Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study

KIWI Study Group

Research output: Contribution to journalArticle

121 Scopus citations

Fingerprint Dive into the research topics of 'Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study'. Together they form a unique fingerprint.

Medicine & Life Sciences